AU2005237364B2 - Method for reducing gastrointestinal toxicity due to the administration of tegafur - Google Patents

Method for reducing gastrointestinal toxicity due to the administration of tegafur Download PDF

Info

Publication number
AU2005237364B2
AU2005237364B2 AU2005237364A AU2005237364A AU2005237364B2 AU 2005237364 B2 AU2005237364 B2 AU 2005237364B2 AU 2005237364 A AU2005237364 A AU 2005237364A AU 2005237364 A AU2005237364 A AU 2005237364A AU 2005237364 B2 AU2005237364 B2 AU 2005237364B2
Authority
AU
Australia
Prior art keywords
tegafur
administration
patient
medicament
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005237364A
Other languages
English (en)
Other versions
AU2005237364A1 (en
Inventor
Hiroshi Ambe
Jun Kuritani
Naruo Nomura
Takeshi Tahara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of AU2005237364A1 publication Critical patent/AU2005237364A1/en
Application granted granted Critical
Publication of AU2005237364B2 publication Critical patent/AU2005237364B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2005237364A 2004-04-29 2005-04-27 Method for reducing gastrointestinal toxicity due to the administration of tegafur Ceased AU2005237364B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56618004P 2004-04-29 2004-04-29
US60/566,180 2004-04-29
PCT/JP2005/008450 WO2005105086A1 (en) 2004-04-29 2005-04-27 Method for reducing gastrointestinal toxicity due to the administration of tegafur

Publications (2)

Publication Number Publication Date
AU2005237364A1 AU2005237364A1 (en) 2005-11-10
AU2005237364B2 true AU2005237364B2 (en) 2010-07-08

Family

ID=35241420

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005237364A Ceased AU2005237364B2 (en) 2004-04-29 2005-04-27 Method for reducing gastrointestinal toxicity due to the administration of tegafur

Country Status (16)

Country Link
US (1) US20080166427A1 (enExample)
EP (1) EP1750703B1 (enExample)
JP (1) JP5376758B2 (enExample)
AT (1) ATE540679T1 (enExample)
AU (1) AU2005237364B2 (enExample)
CY (2) CY1112451T1 (enExample)
DK (1) DK1750703T3 (enExample)
ES (1) ES2378072T3 (enExample)
HR (1) HRP20120293T1 (enExample)
ME (1) ME01335B (enExample)
PL (1) PL1750703T3 (enExample)
PT (1) PT1750703E (enExample)
RS (1) RS52217B (enExample)
RU (1) RU2348409C2 (enExample)
SI (1) SI1750703T1 (enExample)
WO (1) WO2005105086A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010131769A1 (en) * 2009-05-13 2010-11-18 Taiho Pharmaceutical Co., Ltd. Treatment of diffuse-type gastric cancers using s-1 and cisplatin
BR112012000873A2 (pt) * 2009-07-17 2019-11-05 Myriad Genetics Inc método de dosar 5-fluorouracil em uma amostra de um paciente tratado com f-fu ou um pró-fármaco deste, método de tratar um paciente com 5-fluorouracil ou um pró-fármaco deste, método de processamento de uma amostra de sangue de um paciente tratado com um regime compreendendo 5-fluorouracil ou um pró-fármaco deste para um teste de 5-fluorouracil, método de processamento de uma amostra de sangue de um paciente tratado com um regime compreendendo 5-fluorouracil ou um pró-fármaco deste, composição, kit, kit de teste, conjunto de seringa de transferência
WO2011022174A1 (en) * 2009-08-21 2011-02-24 Myriad Genetics, Inc. Method of processing blood samples containing 5-fu
EP2422815A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Pharmaceutical composition of tegafur and natural flavonoid derivative catechin for potentiating antitumour effect and for treating tumours
EP2422784A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Composition of TEGAFUR, caffeic acid phenethyl ester (CAPE) and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
EP2422848A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Composition of tegafur, Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
AU2015227009B2 (en) * 2014-03-06 2019-10-31 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
AU2015238170B2 (en) * 2014-03-28 2019-08-15 L-Nutra Inc. Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
JP6364546B2 (ja) * 2015-04-30 2018-07-25 大鵬薬品工業株式会社 抗腫瘍剤の副作用軽減剤
JP6439761B2 (ja) * 2016-08-09 2018-12-19 トヨタ自動車株式会社 ＮＯｘ吸蔵還元触媒の製造方法
CN106619689B (zh) * 2016-12-30 2018-05-01 陈晓华 一种用于治疗癌症的药物组合物、试剂盒及其应用
MX2022014094A (es) * 2020-05-19 2022-12-08 Cellix Bio Private Ltd Formulaciones farmaceuticas y sus preparaciones para el tratamiento del cancer.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0543015A1 (en) * 1991-05-27 1993-05-26 Taiho Pharmaceutical Co., Ltd. Composition, method and kit for potentiating antitumor activity and for curing tumor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635946A (en) * 1969-07-22 1972-01-18 Solomon Aronovich Giller N1-(2'-furanidyl)-derivatives of 5-substituted uracils
DE3585869D1 (de) * 1984-10-30 1992-05-21 Otsuka Pharma Co Ltd Zusammensetzung zur steigerung der antikrebsaktivitaet einer antikrebsverbindung.
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
DE69003670T2 (de) * 1989-01-05 1994-01-27 Otsuka Pharma Co Ltd Nicht einspritzbares karzinostatisches mittel zur vorbeugung der entzündung durch 5-fluoruracil und verfahren zur behandlung von krebs.
RU2198171C2 (ru) * 1998-10-12 2003-02-10 Леонидов Николай Борисович Новая кристаллическая модификация 5-фтор-1-(тетрагидро-2-фурил)-урацила и комплексные соединения на ее основе, обладающие противоопухолевым действием

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0543015A1 (en) * 1991-05-27 1993-05-26 Taiho Pharmaceutical Co., Ltd. Composition, method and kit for potentiating antitumor activity and for curing tumor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHOLLET P et al. European Journal of Cancer. 2003. 39(9): 1264-1270 *
DAMLE B et al. Clinical Cancer Research. 2001. 7(3): 517-523 *
PETERS GJ et al. Cancer Chemotherapy and Pharmacology. 2003. 52(1): 1-12 *
SAKATA Y et al. European Journal of Cancer. 1998. 34(11): 1715-1720 *

Also Published As

Publication number Publication date
EP1750703B1 (en) 2012-01-11
US20080166427A1 (en) 2008-07-10
ES2378072T3 (es) 2012-04-04
CY2012014I1 (el) 2016-04-13
RU2006142101A (ru) 2008-06-20
CY1112451T1 (el) 2015-12-09
HRP20120293T1 (hr) 2012-04-30
ME01335B (me) 2013-12-20
RU2348409C2 (ru) 2009-03-10
DK1750703T3 (da) 2012-05-07
EP1750703A1 (en) 2007-02-14
JP5376758B2 (ja) 2013-12-25
ATE540679T1 (de) 2012-01-15
AU2005237364A1 (en) 2005-11-10
JP2007534634A (ja) 2007-11-29
PL1750703T3 (pl) 2012-05-31
WO2005105086A1 (en) 2005-11-10
EP1750703A4 (en) 2008-02-27
SI1750703T1 (sl) 2012-02-29
CY2012014I2 (el) 2016-04-13
PT1750703E (pt) 2012-02-23
RS52217B (sr) 2012-10-31

Similar Documents

Publication Publication Date Title
AU2005237364B2 (en) Method for reducing gastrointestinal toxicity due to the administration of tegafur
AU2006209547B2 (en) Anticancer drug containing alpha,alpha,alpha-trifluorothymidine and thymidine phosphorylase inhibitor
US20140057904A1 (en) Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathway
US20110190312A1 (en) Combinations Comprising Epothilones and Protein Tyrosine Kinase Inhibitors and Pharmaceutical Uses Thereof
EA028462B1 (ru) Способы лечения немелкоклеточного рака легких на поздних стадиях c применением комбинированного лечения с ингибитором киназы tor
WO2022109307A1 (en) Treatment of kras mutant cancers
WO2013086002A1 (en) Compositions, process of preparation of said compositions and method of treating cancer
Plano et al. Biowaiver monograph for immediate-release solid oral dosage forms: isavuconazonium sulfate
AU2019344764B2 (en) Quinoline derivative used for treating small cell lung cancer
WO2024238628A1 (en) Treatment of recurrent high-grade glioma or uveal melanoma (um) using a brain-penetrant protein arginine methyltransferase 5 (prmt5) inhibitor
CZ300791B6 (cs) Lécivo pro lécení nádoru nadexprimujících GSH/GSTs systém
AU2006231808B2 (en) Radiotherapy enhancer
Scheulen et al. Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors
US8410096B2 (en) Antitumor agent, kit and method of treating cancer
CN114650816A (zh) 用于治疗胆管癌的包含帕比司他的联合疗法
AU2022343745B2 (en) Therapeutic combinations of orally administered paclitaxel, a p-gp inhibitor, and a checkpoint inhibitor for the treatment of solid tumors
Shirasaka et al. Preclinical and clinical practice of S-1 in Japan
HK40046131A (en) Quinoline derivative used for treating small cell lung cancer
HK1261379B (en) Deuterated compounds for treating cancer and compositions and methods thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired